Top Story Today
Two FDA Reversals in 18 Months: UniQure Gets Green Light to File First-Ever Huntington's Gene Therapy
After telling UniQure its data was sufficient, then insufficient, the FDA reversed course again on June 17 and agreed the company's three-year data would be acceptable as the primary basis of a BLA for AMT-130, a one-time gene therapy injected directly into the brain. The three-year data showed 75% slowing of disease progression in Huntington's patients, a fatal condition with zero approved therapies that address its underlying cause. The stock surged roughly 250% in a single session, driven primarily by the positive clinical data. But the real story is the precedent: accepting a small Phase 1/2 study with external controls as the primary basis for a CNS gene therapy filing sets an unusually low evidentiary bar.
Why it matters: If this filing succeeds, every company developing gene therapies for Alzheimer's, Parkinson's, and ALS will have a new regulatory template. But the FDA's willingness to reverse written agreements multiple times also raises uncomfortable questions about how much any company can trust the guidance it receives.
Read more →Deals and M&A
BioNTech Swallows Its Biggest mRNA Rival (and a $32B Lawsuit) for $1.25 Billion
BioNTech acquired CureVac in an all-stock deal that simultaneously kills patent litigation threatening $32 billion in Comirnaty sales, absorbs a promising oncology pipeline (including a glioblastoma vaccine with 77% immune response rates), and consolidates Europe's mRNA sector from three major players down to two. CureVac's stock had fallen 96% from its pandemic peak, making this a mansion-at-foreclosure-prices situation.
Read more →Incyte Bets $1.25 Billion on a Bleeding Disorder Most People Can't Name
Incyte is paying $1.25 billion upfront (up to $2 billion total) for Vega Therapeutics and its first-in-class von Willebrand disease drug VGA-039. Multi-dose study data showed an 81% reduction in bleeding rates with a once-monthly subcutaneous injection, replacing burdensome IV infusions. With Jakafi patents expiring around 2028, Incyte needs new blockbusters, and analysts see a path to $1 billion in peak sales.
Read more →Novo Nordisk Strikes $812M Deal with an AI Startup to Find Obesity Drugs Beyond GLP-1
The king of Ozempic and Wegovy just signed a research collaboration and exclusive licensing deal worth up to $812 million with Deep Apple Therapeutics, a 2.5-year-old startup using AI and cryo-EM to discover oral obesity drugs targeting a non-incretin pathway. With Lilly's pipeline threatening Novo's dominance, the deal signals that even GLP-1 royalty believes the next era of weight loss will look fundamentally different.
Read more →Private Equity Scoops Up Pharma's Go-To Drug Modeling Software for $375M
Altaris Capital is taking Simulations Plus private at $18.50 per share after the stock dropped over 50% from its 52-week high. The catch: 19 of the top 20 pharma companies use this software to predict how drugs behave in the body. Altaris plans to merge it with molecular design firm CCG, building a vertically integrated computational R&D platform.
Read more →Policy and Regulatory
Medicare's 'Temporary' GLP-1 Benefit Was Engineered to Be Permanent
Starting July 1, eligible Medicare seniors get GLP-1 weight-loss drugs for $50 a month. The 18-month program was built using demonstration authority that bypasses a longstanding statutory ban, with binding manufacturer contracts and legal structures that make reversal nearly impossible. Try taking Zepbound away from 40 million grandparents and see what happens at the ballot box.
Read more →FDA Tells Gene Therapy Developers: Stop Reinventing the Wheel
New draft guidance lets gene therapy sponsors reference existing scientific data instead of regenerating it from scratch, potentially cutting months off development timelines. If another company already validated your CRISPR delivery system, you can cite their work. It's optional, not automatic, but for startups pursuing multiple rare diseases on one platform, the cost savings could be significant.
Read more →FDA Sends Mixed Signals on Moderna's mRNA Flu Shot Before Thursday's Big Vote
FDA briefing documents found "no major deficiencies" in Moderna's mRNA flu vaccine, which showed 26.6% higher efficacy than standard flu shots. But reviewers flagged key gaps: only one season of data, no head-to-head comparison against high-dose vaccines preferred for seniors, and missing data in immunocompromised patients. Thursday's advisory panel vote could determine whether mRNA cracks the $50B flu market.
Read more →Clinical Data and AI
Edgewise Drops Strong HCM Data, Wall Street Sells the Stock Anyway
Edgewise's EDG-7500 showed 90% of obstructive HCM patients improved on blood-flow obstruction, with quality-of-life scores jumping 24 points (five times the clinically meaningful threshold). Crucially, no patient's heart function dropped below safe levels, a persistent concern with competing drugs from BMS and Cytokinetics. The stock still fell 10% because non-obstructive symptom data didn't quite dazzle.
Read more →This Biotech Turned Its Failed Trial Into an AI Training Set
Verge Labs took data from its own failed neurology trial and built an AI model for patient selection, tackling one of drug development's costliest problems. The concept has teeth: researchers applied similar AI to a failed Alzheimer's trial and found a subgroup with 46% slowing of cognitive decline. With 90% of drugs failing in trials, the industry's most expensive mistakes might be its most valuable data.
Read more →